Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Cost-effectiveness 100%
• Outcome Efficacy 100%
• Mediastinoscopy 100%
• Staged Strategy 100%
• Quality-adjusted Life Years 50%
• Life-years Gained 50%
• Incremental Cost-effectiveness Ratio 37%
• Tumor 25%
• T Classification 25%
• Quality-adjusted Life Expectancy 25%
• Chest CT 12%
• Probability Estimates 12%
• Diagnostic Test 12%
• Health Outcomes 12%
• Combined Modality Therapy 12%
• Mediastinal Involvement 12%
• Diagnostic Interventions 12%
• Medical Technology 12%
• Overall Cost 12%
• Health Costs 12%
• Decision-analytic Model 12%
• Risk Cost 12%
• Optimal Strategy 12%
• Societal Perspective 12%
• Risk-benefit 12%
• N3 Disease 12%
• Overall Effectiveness 12%
• Model Estimates 12%
• Multimodal Regimen 12%
• Suvival 12%

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Cost-Effectiveness Analysis 100%
• Mediastinoscopy 100%
• Health Care Cost 62%
• Quality Adjusted Life Year 50%
• Life Expectancy 25%
• Diseases 12%
• Neoplasm 12%
• Computer Assisted Tomography 12%
• Diagnostic Test 12%
• Medical Technology 12%
• Health Outcomes 12%
• Tumor 12%